Drug company Mylan has finalized a $30 million settlement with the Securities and Exchange Commission for alleged accounting and disclosure failures surrounding its popular EpiPen.

Intelligence, benchmarking, and certification for risk and compliance leaders, from the institution setting the standard since 1922.
Drug company Mylan has finalized a $30 million settlement with the Securities and Exchange Commission for alleged accounting and disclosure failures surrounding its popular EpiPen.
We'll send a verification code to %EMAIL%.